Update 2010 – Literaturverzeichnisse - Chemotherapie Journal

*8
Empfehlungen
64. Weigelt J, Itani K, Stevens D, Lau W, et al. Linezolid versus vancomycin
in the treatment of complicated skin and soft tissue infections. Antimicrob
Agents Chemother 2005;49:2260-6.
65. Whitcomb DC. Acute pancreatitis. N Eng J Med 2006;354:2142-50.
66. Witte W, Mielke M. Beta-Laktamasen mit breitem Wirkungsspektrum:
Grundlagen, Epidemiologie, Schlussfolgerungen für die Prävention.
Bundesgesundheitsbl Gesundheitsforsch Gesundheitssch 2004;46:881-
90.
67. Wong PF, Gilliam AD, Kumar S, Shenfine J, et al. Antibiotic regimens
for secondary peritonitis of gastrointestinal origin in adults. Cochrane
Database Syst Rev 2005;CD004539.
8. Infektionen der Nieren und des
Urogenitaltrakts
Florian Wagenlehner, Reinhard Fünfstück, Udo Hoyme, Martin Kaase, Eberhard Kniehl,
Johannes Knobloch, Kurt Naber
Literatur
1. Aronoff G, Brater DC, Schrier R, Bennett WM. Use of drugs in patients
with renal insufficiency. Workshop report. Blood Purif 1994;12:14-9.
2. Bailey RR, Begg EJ, Smith AH, Robson, RA. Prospective, randomized,
controlled study comparing two dosing regimens of gentamicin/oral
ciprofloxacin switch therapy for acute pyelonephritis. Clin Nephrol
1996;46:183-6.
3. Bichler KH, Eipper E, Naber K, Braun V. Urinary infection stones. Int J
Antimicrob Agents 2002;19:488-98.
4. Bjerklund Johansen TE, Cek M, Naber K, Stratchounski LP. Prevalence of
hospital-acquired urinary tract infections in urology departments. Eur
Urol 2007;51:1100-12.
5. Botto H, Naber KG, Bishop MC, Jarlier V. Antibiotic policy in prophylaxis
and treatment of nosocomial urinary tract infection. In: Naber KG,
Pechere JC, Kumazawa J, Khoury S (eds.). Nosocomial and health care
associated infections in urology. Plymouth, UK: Plymbridge Distributors;
2001:179-91.
6. Bouvier d`Yvoir MJY, Maire PH. Dosage regimens of antibacterials. Clin
Drug Invest 1996;11:229-39.
7. Dellinger RP, Levy MM, Carlet JM, Bion J, et al. Surviving Sepsis Campaign:
international guidelines for management of severe sepsis and
septic shock: 2008. Intensive Care Med 2008;34:17-60.
8. Dellinger RP, Levy MM, Carlet JM, Bion J, et al. Surviving Sepsis Campaign:
international guidelines for management of severe sepsis and
septic shock: 2008. Crit Care Med 2008;36:296-327.
9. Elhanan G, Sarhat M, Raz R. Empiric antibiotic treatment and the misuse
of culture results and antibiotic sensitivities in patients with community-acquired
bacteraemia due to urinary tract infection. J Infect
1997;35:283-8.
10. Fünfstück R, Stein G. Asymptomatische Bakteriurie. Nieren- und Hochdruckkrankheiten
2007;26:269-78.
11. Giamarellou H. Clinical experience with the fourth generation cephalosporins.
J Chemother 1996;8:91-104.
12. Grabe M, Bishop MC, Bjerklund-Johansen TE, Botto H. Guidelines on
urological infections. In: European Association of Urology Guidelines.
Vol. 2009 edition. Arnhem, Netherlands: European Association of Urology,
2009:1-110.
13. Hoyme UB. Tuboovarialabszess, Pelve-operitonitis und septischer
Schock. Gynäkologe 2002;4:353-62.
14. Jacobson L, Westrom L. Objectivized diagnosis of acute pelvic inflammatory
disease. Diagnostic and prognostic value of routine laparoscopy. Am
J Obstet Gynecol 1969;105:1088-98.
15. Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, et al. A prospective, multicenter,
randomized, double-blind study comparing ertapenem and ceftriaxone
followed by appropriate oral therapy for complicated urinary
tract infections in adults. Urology 2005;60:16-22.
16. Johansen TE, Cek M, Naber KG, Stratchounski L, et al. Hospital acquired
urinary tract infections in urology departments: pathogens, susceptibility
and use of antibiotics. Data from the PEP and PEAP-studies. Int J
Antimicrob Agents 2006;28:91-107.
17. Kumar A, Roberts D, Wood KE, Light B, et al. Duration of hypotension
before initiation of effective antimicrobial therapy is the critical determinant
of survival in human septic shock. Crit Care Med 2006;34:1589-
96.
18. Livengood III CH. Tubo-ovarian abscess. In: Mead PB, Hager WD, Faro S
(eds.). Protocols for infectious diseases in obstetrics and gynecology. 2nd
edition. Malden: Blackwell Science Inc., 2000: 412-8.
19. Mandell LA, Bergeron MG, Ronald AR, Vega C, et al. Once-daily therapy
with ceftriaxone compared with daily multiple-dose therapy with
Chemotherapie Journal 19. Jahrgang · Heft 6 · 2010
cefotaxime for serious bacterial infections: a randomized, double-blind
study. J Infect Dis 1989;160:433-41.
20. Millan-Rodriguez F, Palou J, Bujons-Tur A, Musquera-Felip M, et al. Acute
bacterial prostatitis: two different sub-categories according to a previous
manipulation of the lower urinary tract. World J Urol 2006;24:45-50.
21. Naber KG, Eisenstein BI, Tally FP. Daptomycin versus ciprofloxacin in
the treatment of complicated urinary tract infection due to grampositive
bacteria. Infect Dis Clin Pract 2004;12:322-7.
22. Naber KG, Hauke W. Cefpodoxime proxetil in patients with acute uncomplicated
pyelonephritis. International, prospective, randomized
comparative study versus ciprofloxacin in general practice. Chemother
J 2001;10:29-34.
23. Naber KG, Landen H. Rapid resolution of symptoms with ciprofloxacin
therapy in 3,859 hospitalised patients with urinary tract infection. Int J
Antimicrob Agents 2004;23:35-40.
24. Naber KG, Llorens L, Kaniga K, Kotey P, et al. Intravenous doripenem
at 500 milligrams versus levofloxacin at 250 milligrams, with an option
to switch to oral therapy, for treatment of complicated lower urinary
tract infection and pyelonephritis. Antimicrob Agents Chemother
2009;53:3782-92.
25. Naber KG, Savov O, Salmen HC. Piperacillin 2 g/tazobactam 0.5 g is as
effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute
uncomplicated pyelonephritis and complicated urinary tract infections.
Int J Antimicrob Agents 2002;19:95-103.
26. Naber KG, Schito G, Botto H, Palou J, et al. Surveillance study in Europe
and Brazil on clinical aspects and antimicrobial resistance epidemiology
in females with cystitis (ARESC): implications for empiric therapy. Eur
Urol 2008;54:1164-75.
27. Naber KG, Timmler R. Keimelimination durch Fosfomycin bei komplizierten
Harnwegsinfektionen. Therapiewoche 1983;33:3300-6.
28. Ooi ST, Frazee LA, Gardner WG. Management of asymptomatic bacteriuria
in patients with diabetes mellitus. Ann Pharmacother 2004;38:
490-3.
29. Pea F, Viale HP, Furlanut M. Antimicrobial therapy in critically ill patients:
a review of pathophysiological conditions responsible for altered
disposition and pharmacokinetic variability. Clin Pharmacokinet
2005;44:1009-34.
30. Peterson J, Kaul S, Khashab M, Fisher AC, et al. A double-blind, randomized
comparison of levofloxacin 750 mg once-daily for five days with
ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of
complicated urinary tract infections and acute pyelonephritis. Urology
2008;71:17-22.
31. Prevention CfDCa. Sexually transmitted disease treatment guidelines.
MMWR 2006;55:1-94.
32. Richard GA, Klimberg IN, Fowler CL, Callery-D‘Amico S, et al. Levofloxacin
versus ciprofloxacin versus lomefloxacin in acute pyelonephritis.
Urology 1998;52:51-5.
33. Schaeffer AJ, Anderson RU, Krieger JN, Lobel B, et al. Consensus statement
on prostatitis. The assessment and management of male pelvic
pain syndrome, including prostatitis. In: 6th International Conference
on New Developments in Prostate Cancer and Prostate Diseases, M. L. U.
T. D. Edition, Ed, Health Publications, Paris, 2006:343-75.
34. Schmechel H, Fünfstück R, Folger U, Robiller F, et al. Kritische Betrachtung
der rechnerischen Bestimmung der glomerulären Filtrationsrate
nach Cockroft und Gault – Versuch einer Korrektur. Nieren- und Hochdruckkrankheiten
2005;10:433-44.
35. Stein G, Eichhorn T, Fünfstück R. Harnwegsinfektionen bei Patienten
mit eingeschränkter Nierenfunktion.- Nieren- und Hochdruckkrankheiten
2007;36:288-91.
36. Swan SK, Bennett WM. Drug dosing guidelines in patients with renal
failure. West J Med 1992;156:633-8.
37. Sweet RL. Pelvic Inflammatory Disease: Treatment. In: Mead PB, Hager
WD, Faro S (eds.). Protocols for infectious diseases in obstetrics and gynecology.
2nd edition. Malden: Blackwell Science Inc., 2000:400-5.
38. Talan DA, Stamm WE, Hooton TM, Moran GJ, et al. Comparison of ciprofloxacin
(7 days) and trimethoprim-sulfamethoxazole (14 days) for acute
uncomplicated pyelonephritis in women: a randomized trial. JAMA
2000;283:1583-90.
39. Tenke P, Kovacs B, Bjerklund Johansen TE, Matsumoto T, et al. European
and Asian guidelines on management and prevention of catheter-associated
urinary tract infections. Int J Antimicrob Agents 2008;31:68-78.
40. Townsend SR, Schorr C, Levy MM, Dellinger RP. Reducing mortality in severe
sepsis: the Surviving Sepsis Campaign. Clin Chest Med 2008;29:721-
33.
41. Wagenlehner FM, Krcmery S, Held C, Klare I, et al. Epidemiological
analysis of the spread of pathogens from a urological ward using genotypic,
phenotypic and clinical parameters. Int J Antimicrob Agents
2002;19:583-91.
42. Wagenlehner FM, Lehn N, Witte W, Naber KG. In vitro activity of daptomycin
versus linezolid and vancomycin against gram-positive uropatho-